PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.06 - 0.07
0.06 - 0.24
1.89M / 3.59M (Avg.)
-1.60 | -0.04
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1304718.43%
10Y CAGR of 1304718.43% while CRN.AX is zero. Bruce Berkowitz would see if incremental growth can widen into a significant edge.
307.22%
5Y CAGR of 307.22% while CRN.AX is zero. Bruce Berkowitz would see if small improvements can scale into a larger advantage.
68.52%
Positive 3Y CAGR while CRN.AX is negative. John Neff might view this as a sharp short-term edge or successful pivot strategy.
48.56%
OCF/share CAGR of 48.56% while CRN.AX is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
-183.46%
Negative 5Y OCF/share CAGR while CRN.AX is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-545.17%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
35.69%
10Y net income/share CAGR of 35.69% while CRN.AX is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
88.08%
Net income/share CAGR of 88.08% while CRN.AX is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
-70.46%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
No Data
No Data available this quarter, please select a different quarter.
88.98%
Equity/share CAGR of 88.98% while CRN.AX is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
-3408.92%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.